A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability,
pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with
advanced solid tumors. The Recommended dose for phase II trial （RP2D） will be determined
based on the safety, tolerability, pharmacokinetics and efficacy.